Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) kicked off on Friday, up 2.08% from the previous trading day, before settling in for the closing price of $0.27. Over the past 52 weeks, ADAP has traded in a range of $0.20-$1.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 193.37% over the past five years. While this was happening, its average annual earnings per share was recorded -74.52%. With a float of $228.63 million, this company’s outstanding shares have now reached $257.85 million.
Let’s look at the performance matrix of the company that is accounted for 506 employees. In terms of profitability, gross margin is 98.06%, operating margin of -36.31%, and the pretax margin is -38.17%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.33%, while institutional ownership is 34.06%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -74.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.83% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Take a look at Adaptimmune Therapeutics Plc ADR’s (ADAP) current performance indicators. Last quarter, stock had a quick ratio of 1.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) saw its 5-day average volume 0.49 million, a negative change from its year-to-date volume of 1.62 million. As of the previous 9 days, the stock’s Stochastic %D was 41.56%. Additionally, its Average True Range was 0.03.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 17.35%, which indicates a significant decrease from 42.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.85% in the past 14 days, which was lower than the 119.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2790, while its 200-day Moving Average is $0.6460. Nevertheless, the first resistance level for the watch stands at $0.2901 in the near term. At $0.3000, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3151. If the price goes on to break the first support level at $0.2651, it is likely to go to the next support level at $0.2500. The third support level lies at $0.2401 if the price breaches the second support level.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
The company with the Market Capitalisation of 72.22 million has total of 261,522K Shares Outstanding. Its annual sales at the moment are 178,030 K in contrast with the sum of -70,810 K annual income. Company’s last quarter sales were recorded 7,290 K and last quarter income was -47,580 K.
